Immunome Inc (IMNM)

$20.14 -0.43 (-2.09%)
Market Cap 1.89B
Revenue (ttm) 9.04M
Net Income (ttm) -292.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,240.71%
Debt to Equity Ratio 0.00
Volume 2,664,200
Avg Vol 2,180,986
Day's Range N/A - N/A
Shares Out 91.71M
Stochastic %K 35%
Beta 2.22
Analysts Strong Sell
Price Target $34.25

Company Profile

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 939 7410
Address:
18702 North Creek Parkway, Suite 100, Bothell, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 14 at 12:28 PM
$IMNM RSI: 35.26, MACD: 0.2958 Vol: 1.06, MA20: 21.09, MA50: 19.16 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Cryptocr7
Cryptocr7 Jan. 13 at 7:38 PM
$IMNM could get a bump tomorrow and rest of the week with CEO at JPM Healthcare conference tomorrow
1 · Reply
RadioIsotope25
RadioIsotope25 Jan. 11 at 9:38 PM
$RADX strains more ownership in Radiopharm Ventures now at 87.5% yielding a basket of new therapeutics. B7-H3 created with the collaboration is now Phase 1 approved. Radiopharm Ventures = MD Anderson + Radiopharm Theranostics. Trading at 5-6% value of $AKTS with a more advanced diversified pipeline. $IMNM $MNPR
2 · Reply
W15E
W15E Jan. 11 at 4:30 PM
$IMNM 🤔
0 · Reply
EingeLTrade
EingeLTrade Jan. 9 at 5:31 PM
$IMNM
0 · Reply
Elliotwavedave
Elliotwavedave Jan. 7 at 1:52 AM
$IMNM https://x.com/aponiaanalytics/status/2008612862349185166?s=46&t=9IU2_XHzwzFLsVH7RJTUPA
0 · Reply
redrussian
redrussian Jan. 6 at 6:32 PM
$IMNM added more (chairman acquired 5.8% more stock)also presenting today at a JPM healthcare conference
0 · Reply
EingeLTrade
EingeLTrade Jan. 6 at 3:26 PM
🔑 Key re-test month for $IMNM
0 · Reply
Elliotwavedave
Elliotwavedave Jan. 6 at 11:54 AM
$IMNM good ol Jim Cramer.
1 · Reply
TrendEdgeLogan
TrendEdgeLogan Jan. 3 at 4:31 PM
$IMNM $2.4B mc $XBI name seeing more UNPLANNED open mkt insider buys by President & CEO this pas week. $100K purchase, adding to this $1M purchase on 12/18/25. We have seen a ton of insider buying activity here over the past 2 years TrendEdge.app/asset/IMNM
1 · Reply
Latest News on IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 4:05 PM EST - 5 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 8 days ago

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat

Dec 17, 2025, 2:44 PM EST - 27 days ago

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat

Immunome Announces Pricing of Public Offering of Common Stock

Dec 16, 2025, 8:16 PM EST - 4 weeks ago

Immunome Announces Pricing of Public Offering of Common Stock

Immunome Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 4 weeks ago

Immunome Announces Proposed Public Offering of Common Stock

Immunome's experimental drug meets main goal in late-stage study

Dec 15, 2025, 7:16 AM EST - 4 weeks ago

Immunome's experimental drug meets main goal in late-stage study

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 15, 2025, 7:00 AM EST - 4 weeks ago

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 14, 2025, 4:00 PM EST - 4 weeks ago

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome to Present at Upcoming Investor Conferences

Nov 25, 2025, 8:00 AM EST - 7 weeks ago

Immunome to Present at Upcoming Investor Conferences

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 2 months ago

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Oct 31, 2025, 11:51 AM EDT - 2 months ago

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Oct 23, 2025, 12:00 PM EDT - 2 months ago

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Infinimmune Announces Research Collaboration with Immunome

Sep 18, 2025, 8:00 AM EDT - 4 months ago

Infinimmune Announces Research Collaboration with Immunome

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 4 months ago

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Aug 11, 2025, 10:31 PM EDT - 5 months ago

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 8 months ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Immunome: Transformed Pipeline Offers Multiple Catalysts

Apr 17, 2025, 6:06 AM EDT - 9 months ago

Immunome: Transformed Pipeline Offers Multiple Catalysts

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 8:00 AM EDT - 10 months ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:05 PM EDT - 10 months ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Mar 10, 2025, 7:41 AM EDT - 11 months ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Immunome to Present at Upcoming March Conferences

Feb 25, 2025, 8:00 AM EST - 11 months ago

Immunome to Present at Upcoming March Conferences

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2025, 4:01 PM EST - 1 year ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Can Take The Fight To Competitors With Varegacestat

Jan 30, 2025, 10:27 AM EST - 1 year ago

Immunome Can Take The Fight To Competitors With Varegacestat

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 29, 2025, 11:11 PM EST - 1 year ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Oct 8, 2024, 8:05 AM EDT - 1 year ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Jun 27, 2024, 2:14 PM EDT - 1 year ago

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Immunome Appoints Phil Tsai as Chief Technical Officer

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome Announces Completion of Purchase of Assets from Atreca

May 20, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 17, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome Appoints Kinney Horn as Chief Business Officer

May 2, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Kinney Horn as Chief Business Officer

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 25, 2024, 8:26 AM EDT - 1 year ago

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 5, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Immunome: An Oncology Powerhouse In The Making

Apr 2, 2024, 2:07 PM EDT - 1 year ago

Immunome: An Oncology Powerhouse In The Making

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Mar 28, 2024, 4:02 PM EDT - 1 year ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Mar 18, 2024, 5:44 AM EDT - 1 year ago

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Mar 7, 2024, 8:00 AM EST - 2 years ago

Immunome to Participate in the Leerink Partners Global Biopharma Conference

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 14 at 12:28 PM
$IMNM RSI: 35.26, MACD: 0.2958 Vol: 1.06, MA20: 21.09, MA50: 19.16 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Cryptocr7
Cryptocr7 Jan. 13 at 7:38 PM
$IMNM could get a bump tomorrow and rest of the week with CEO at JPM Healthcare conference tomorrow
1 · Reply
RadioIsotope25
RadioIsotope25 Jan. 11 at 9:38 PM
$RADX strains more ownership in Radiopharm Ventures now at 87.5% yielding a basket of new therapeutics. B7-H3 created with the collaboration is now Phase 1 approved. Radiopharm Ventures = MD Anderson + Radiopharm Theranostics. Trading at 5-6% value of $AKTS with a more advanced diversified pipeline. $IMNM $MNPR
2 · Reply
W15E
W15E Jan. 11 at 4:30 PM
$IMNM 🤔
0 · Reply
EingeLTrade
EingeLTrade Jan. 9 at 5:31 PM
$IMNM
0 · Reply
Elliotwavedave
Elliotwavedave Jan. 7 at 1:52 AM
$IMNM https://x.com/aponiaanalytics/status/2008612862349185166?s=46&t=9IU2_XHzwzFLsVH7RJTUPA
0 · Reply
redrussian
redrussian Jan. 6 at 6:32 PM
$IMNM added more (chairman acquired 5.8% more stock)also presenting today at a JPM healthcare conference
0 · Reply
EingeLTrade
EingeLTrade Jan. 6 at 3:26 PM
🔑 Key re-test month for $IMNM
0 · Reply
Elliotwavedave
Elliotwavedave Jan. 6 at 11:54 AM
$IMNM good ol Jim Cramer.
1 · Reply
TrendEdgeLogan
TrendEdgeLogan Jan. 3 at 4:31 PM
$IMNM $2.4B mc $XBI name seeing more UNPLANNED open mkt insider buys by President & CEO this pas week. $100K purchase, adding to this $1M purchase on 12/18/25. We have seen a ton of insider buying activity here over the past 2 years TrendEdge.app/asset/IMNM
1 · Reply
Smellmahass
Smellmahass Jan. 3 at 12:12 AM
$IMNM Oh dear had to sell for loss. Disappointed.
0 · Reply
FRAGMENTS
FRAGMENTS Jan. 2 at 12:15 AM
$DIA $CLPR $IMNM $MDBH
0 · Reply
FRAGMENTS
FRAGMENTS Jan. 1 at 3:40 PM
$DIA January isn’t “new year, new trend.” January is AUDIT SEASON. 🧾 Guidance. Covenants. Inventory. Credit marks. Receipts > vibes. Just dropped: FRAGMENTS — Deep Value Watchlist (Jan 2026) 🔍 A pricing audit of 10 names the market is haircutt-ing by category. 3 visible. 7 locked for PLUS. 🔒 HERE:https://cundilldeepvalue.substack.com/p/deep-value-watchlist-january-2026 $CLPR $IMNM $MDBH
0 · Reply
deedeethegenius
deedeethegenius Dec. 31 at 7:30 PM
$IMNM
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 31 at 1:50 AM
$IMNM CEO purchased 4,729 shares at $21.15 for a total of $100,018. SIEGALL CLAY B now owns 665,254 shares. https://ceo-buys.com
0 · Reply
Smellmahass
Smellmahass Dec. 30 at 11:54 PM
$IMNM CEO bought shares again.
1 · Reply
Smellmahass
Smellmahass Dec. 30 at 1:47 PM
$IMNM $IONQ Dont think so wrong ticker.
0 · Reply
Smellmahass
Smellmahass Dec. 30 at 1:47 PM
$IMNM Wrong ticker lol.
0 · Reply
BasicInstinct
BasicInstinct Dec. 30 at 1:32 PM
$IMNM next OFFERING RELEASE $IONQ 💯
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 30 at 1:31 PM
$IMNM Offering here IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
0 · Reply
LegislativeL
LegislativeL Dec. 25 at 1:31 PM
$IMNM Expectations are shifting from future promises toward demonstrated capability. Resource allocation will signal whether leadership prioritizes endurance or speed. Without proof, upside scenarios remain hypothetical and heavily discounted. Risk remains manageable if management converts plans into consistent outputs.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 22 at 2:45 PM
$IMNM CEO purchased 7,278 shares at $20.48 for a total of $149,053. SIEGALL CLAY B now owns 860,525 shares. https://ceo-buys.com
0 · Reply